UCB (UCBJF) Stock Price, News & Analysis

Company Overview

UCB S.A. is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline. Notable medicines associated with UCB include Cimzia (certolizumab pegol), used in inflammatory and autoimmune conditions, and antiepileptic agents such as levetiracetam (Keppra) and brivaracetam (Briviact). UCB invests in R&D across discovery, clinical development and lifecycle management and frequently collaborates with academic groups, biotechnology partners and contract research organizations to advance novel mechanisms and delivery approaches.

Headquartered in Brussels, UCB operates internationally, serving patients and healthcare systems across Europe, North America, Asia-Pacific and other regions. The company is managed through an executive leadership team and overseen by a board of directors; it also maintains manufacturing, regulatory and commercial functions to support global product supply and market access. UCB’s strategic priorities emphasize scientific innovation, targeted therapeutic development and partnerships aimed at addressing unmet medical needs in neurology and immunology.

Key Stats

• Today's Range: $280.85 to $285.13
• 50-Day Range: $273.54 to $334.09
• 52-Week Range: $168.65 to $345.39
• Volume: 138 shs
• Average Volume: 722 shs
• Market Capitalization: $53.09 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Company Calendar

• Today: 5/08/2026
• Next Earnings (Estimated): 7/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:UCBJF
• CIK: 1290640
• Web: www.ucb.com
• Phone: (322) 559-9999
• Fax: 32-2559-9900
• Employees: 9,083
• Year Founded: 1928

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 1.19
• Quick Ratio: 0.78

Sales & Book Value

• Annual Sales: $5.27 billion
• Price / Sales: 10.08
• Cash Flow: $12.06 per share
• Price / Cash Flow: 23.28
• Book Value: $50.52 per share
• Price / Book: 5.56

Miscellaneous

• Outstanding Shares: 189,020,000
• Free Float: N/A
• Market Cap: $53.09 billion
• Optionable: Not Optionable
• Beta: 0.47